Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Anti-Osteoanabolic Function of Sclerostin Is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research - 1 Jul 2015

Yorgan Timur A, Peters Stephanie, Jeschke Anke, Benisch Peggy, Jakob Franz, Amling Michael, Schinke Thorsten

Abstract excerpt

Activating mutations of the putative Wnt co-receptor Lrp5 or inactivating mutations of the secreted molecule Sclerostin cause excessive bone formation in mice and humans. Previous studies have suggested that Sclerostin functions as an Lrp5 antagonist, yet clear in vivo evidence was still missing, and alternative mechanisms have been discussed. Moreover, because osteoblast-specific inactivation of β-catenin, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone and Bones
Share to Bone Remodeling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Collagen Type I

Share to Intercellular Signaling Peptides and Proteins

Share to Low Density Lipoprotein Receptor-Related Protein-5

Share to Organ Size

Share to Osteoblasts

Share to X-Ray Microtomography

Source

Identifiers

PMID: 25640331
DOI: 10.1002/jbmr.2461

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Anti-Osteoanabolic Function of Sclerostin Is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5.PMID 25640331Read ↗

LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST.Semantic proximity Read ↗

An Additional Lrp4 High Bone Mass Mutation Mitigates the Sost-Knockout Phenotype in Mice by Increasing Bone Remodeling.Semantic proximity Read ↗

Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta.Semantic proximity Read ↗

Lrp4 Mediates Bone Homeostasis and Mechanotransduction through Interaction with Sclerostin In VivoSemantic proximity Read ↗

High-bone-mass-producing mutations in the Wnt signaling pathway result in distinct skeletal phenotypes.Semantic proximity Read ↗

Bone Density Ligand, Sclerostin, Directly Interacts With LRP5 but Not LRP5G171V to Modulate Wnt ActivitySemantic proximity Read ↗

Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo.Semantic proximity Read ↗

Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.Semantic proximity Read ↗

Enhancing Wnt signaling lowers fracture incidence in a severe mouse model of Osteogenesis ImperfectaSemantic proximity Read ↗

Osteocyte-Derived Sclerostin Inhibits Bone Formation: Its Role in Bone Morphogenetic Protein and Wnt SignalingSemantic proximity Read ↗

Targeted deletion of <i>Sost</i> distal enhancer increases bone formation and bone massSemantic proximity Read ↗

Lrp5 functions in bone to regulate bone mass.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.